Fatima Faraz

Fatima Faraz

Auto-generated profile, based on publicly available information

Fatima Faraz

Department of Medicine, Rawalpindi Medical University, Rawalpindi, Pakistan

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 May 2023 in Current Problems in Cardiology
Verified
Journal Article
Closed access
ZDZainab Atiyah Dakhil
Zainab Atiyah Dakhil
HFHasan Ali Farhan
Hasan Ali Farhan
FFFatima Faraz
Fatima Faraz
MSMoatamn Reda Skuk
Moatamn Reda Skuk
MAMay Saad Al-Jorani
May Saad Al-Jorani
TÖTuğba Kemaloğlu Öz
Tuğba Kemaloğlu Öz

7 January 2024 in Health Science Reports
Verified
Journal Article
Open access
AFAreeba Fareed
Areeba Fareed
AHAariz Hussain
Aariz Hussain
FFFatima Faraz
Fatima Faraz
RSRima Siblini
Rima Siblini
Background and Aims: This research paper discusses Pakistan's healthcare systems' challenges in managing the monkeypox outbreak in Pakistan. Monkeypox is a zoonotic viral disease caused by the monkeypox virus. The World Health Organization declared it a global public health emergency due to the surge in cases worldwide. Pakistan reported its first verified case in April 2023, necessitating immediate response.Body: This correspondence emphasizes on early detection, rapid diagnostic testing, and prompt treatment to limit the virus's transmission. Prevention strategies such as vaccination and travel restrictions on suspected cases are crucial for containment. Lessons from controlling the coronavirus disease 2019 pandemic can inform strategies for monkeypox.Conclusion: The recent outbreak of monkeypox has presented challenges to healthcare systems. Therefore, a coordinated approach involving healthcare providers, government organizations, and the public is crucial in controlling the monkeypox outbreak. Further research is necessary to understand the virus and develop effective interventions for future outbreaks.

2 February 2024 in The American Journal of Surgery
Verified
Journal Article
Closed access
SASyed Muhammad Muneeb Akhtar
Syed Muhammad Muneeb Akhtar
AFAreeba Fareed
Areeba Fareed
UAUrwah Afzal
Urwah Afzal
MAMuhammad Sohaib Asghar
Muhammad Sohaib Asghar
MMMunazza Mumtaz
Munazza Mumtaz
RVRayyan Vaid
Rayyan Vaid


22 February 2024 in Cancer Reports
Verified
Journal Article
Open access
MRMohammad Ebad Ur Rehman
Mohammad Ebad Ur Rehman
FFFatima Faraz
Fatima Faraz
HCHuzaifa Ahmad Cheema
Huzaifa Ahmad Cheema
OAOmer S. Ashruf
Omer S. Ashruf
HRHamna Raheel
Hamna Raheel
Sarya SwedSarya Swed
Sarya Swed
Background: Individuals with a Prior Cancer History (PCH) are often excluded from clinical trials. However, a growing body of evidence suggests that prior cancer history does not present adverse outcomes on cancer patients. The evidence on the survival of brain cancer patients in this regard remains widely unknown.Methods: We conducted a retrospective cohort study to estimate the prevalence and impact of prior cancer on survival of patients diagnosed with brain cancer. Data of patients who were diagnosed with brain cancer as their first or second primary malignancy between 2000 and 2019 were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. Propensity Score Matching (PSM) was used to ensure comparable baseline characteristics among the patients. Survival analysis was conducted using the Kaplan–Meier method, as well as multivariate Cox proportional hazard and multivariate competing risk models.Results: Out of 42 726 patients, 1189 (2.78%) had PCH. Genitourinary (40.4%), Breast (13.6%), Hematologic and Lymphatic (11.4%), and Gastrointestinal malignancies (11.3%) were the most common types of prior cancer. PCH served as a significant risk factor for Overall Survival (OS) (Adjusted Hazard Ratio [AHR] 1.26; 95% CI [1.15–1.39]; p < .001) but did not have a statistically significant impact on Brain Cancer‐Specific Survival (BCSS) (AHR 0.97; 95% CI [0.88–1.07]; p = .54). Glioblastoma exhibited the most substantial and statistically significant impact on survival as compared to other histological types. Of all the organs systems, only prior Gastrointestinal and Hematologic and Lymphatic malignancies had a statistically significant impact on OS of patients.Conclusion: Our findings indicate that PCH does not exert a substantial impact on the survival of brain cancer patients, except in cases involving gastrointestinal or hematologic and lymphatic PCH, or when the brain cancer is glioblastoma.

1 July 2025 in BMJ Open Quality
Verified
Journal Article
Open access
PDF file
JAJawairia Altaf
Jawairia Altaf
AAAhmed Hasan Ashfaq
Ahmed Hasan Ashfaq
NRNida Riaz
Nida Riaz
FFFatima Faraz
Fatima Faraz
Informed consent is a fundamental element of clinical practice. A well-structured and understandable consent form not only upholds patients’ rights but also protects clinicians against medicolegal risks. This quality improvement project aimed to identify deficiencies in the consenting process for surgical procedures and implement changes to enhance patient care. The project was conducted in the Ear Nose Throat Department at Holy Family Hospital, Rawalpindi, a large tertiary care centre serving a predominantly low socioeconomic population in Pakistan. A total of 80 patients were included across two cycles (40 patients per cycle). Structured interviews and questionnaires were used to assess patient understanding of informed consent components. Key areas for improvement were identified. Educational sessions for doctors were organised and a new, detailed consent form was introduced. The project followed the Plan-Do-Study-Act methodology. Baseline measurements in cycle 1 showed that 15% (n=6) of consent forms were incomplete, reduced to 0% postintervention. A written explanation of the procedure was missing in 57.5% (n=23) of cases initially, improving to 10% (n=4) in cycle 2. Potential complications were not recorded in 37.5% (n=15) of cases at baseline, falling to 10% (n=4) after intervention. Verbal explanation of the procedure was omitted in 32.5% (n=13) of cases initially, reduced to 5% (n=2) postintervention. Documentation of the right to withdraw was absent in 12.5% (n=5) of cases in cycle 1, with full compliance achieved in cycle 2. This project demonstrates that targeted educational interventions and structured consent documentation can significantly improve the quality of the consenting process, promoting safer and more patient-centred care.